▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4003 by analyst upside · 2026-11-13
SLN
Silence Therapeutics plc
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
-0.3%
implied upside to consensus target
Current Price $19.8
Consensus Target $19.75
Bull Target $20.0
Bear Target $19.0
Analysts Covering 4
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
1
Hold
3
Sell
0
52-Week Low $4.19
52-Week High $19.86
YTD Return +222.0%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.29
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.19
52-Week High $19.86
Current Price $19.8
Bear Target $19.0
Bull Target $20.0
● Now $19.8 ● Target $19.75
TRADING DATA
Avg Volume 2.5M
YTD Return +222.0%
Analyst Count 4
Consensus Hold
Upside to Target -0.3%
Last Updated 2026-11-13

ANALYST SUMMARY

Silence Therapeutics plc (SLN) is currently trading at $19.8 with a Wall Street consensus price target of $19.75, which is 0.3% below the current price over the next 12 months. 4 analysts currently cover SLN, with a consensus rating of Hold - 25% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $19.0.

SLN operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 222.0% year-to-date and is currently trading near the upper end of its 52-week range of $4.19 – $19.86.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SLN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-10-21 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-08-11 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-06-24 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-06-17 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-13 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-09-16 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-06-13 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
12/30
Consensus clarity
29/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →